Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — JP Morgan Conference January 2020
23 slides from Ideaya Biosciences's conference presentation, Jan 13, 2020
Slide 1: IDEAYA Biosciences Corporate Presentation, JP Morgan Conference January 2020
IDEAYA Biosciences Corporate Presentation JP Morgan Conference January 2020 Exhibit 99.1 “[COMPANY LOGO]”
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainti
Slide 3: IDEAYA Highlights
IDEAYA HIGHLIGHTS Synthetic Lethality (SL) Direct Targeting of Oncogenic Pathways PRECISION MEDICINE TARGET CLASSES IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability Muta
Slide 4: IDEAYA's Precision Medicine Oncology Pipeline
IDEAYA’s Precision Medicine Oncology Pipeline Indication Biomarker Preclinical IND Phase 1 Phase 2 Registration Enabling Status IDE196 PKC inhibitor MUM Mono GNAQ/11 Target Single-Arm Ph2 Trial Q1’20 Potential Registration-Enabling Non-MUM Solid Tumors GNAQ/11 Ph1/2 Basket Trial Enrollment Ongoing S
Slide 5: IDE196: Potential First-in-Class PKC Inhibitor Targeting GNAQ/GNA11 Mutation Solid Tumors
IDE196: Potential First-in-Class Protein Kinase C (PKC) Inhibitor Targeting GNAQ/GNA11 Mutation Solid Tumors & Mediated Diseases Van Raamsdonk, CD, et. al, Nature 2009; Van Raamsdonk CD, et. al, NEJM 2010; Piperno-Neumann S, et. al, J Clin Oncol 2014; Oncotarget, May 2016, Carita et al IDE196: Poten
Slide 6: Metastatic Uveal Melanoma (MUM)
Metastatic Uveal Melanoma (MUM) Removal of the eye (”enucleation”) Surgery to save eye Radiation treatment - Iodine-125 plaque - Proton beam Other treatments - Laser, tumor resection Treatment Options for Primary Disease ~ 90% of uveal melanoma patients harbor activating GNAQ or GNA11 mutation ~ 50%
Slide 7: IDE196 Phase 1 Dose Escalation Monotherapy Results in MUM
IDE196 Phase 1 Dose Escalation Monotherapy Results Metastatic Uveal Melanoma (MUM) AACR 2019, Novartis Data; Data cut-off: Sep 30 2018; Response data by investigator assessment Treatment LXS196 200 mg BID LXS196 300 mg BID LXS196 400 mg BID -30 22/30 (73%) Disease Control Rate (SD+PR+CR) 8/30 (27%)
Slide 8: GNAQ/GNA11 Basket Trial to Evaluate Additional Solid Tumors
GNAQ/GNA11 Basket Trial to Evaluate Additional Solid Tumors GNAQ/GNA11 mutations listed on Foundation NGS panel GNAQ/GNA11 mutations listed on ctDNA liquid biopsy panel GNAQ/GNA11 mutations listed on ctDNA liquid biopsy panel Point Mutations (SNVs) (73 Genes) AKT1 ALK APC AR BRAF BRCA1 BRCA2 CCND1 C
Slide 9: Biological Rationale for PKC-delta/epsilon + MEK Clinical Combinations
Biological Rationale for PKC-delta/epsilon + MEK Clinical Combinations to Enhance Response IDE196 + MEK Combo Demonstrates Synergy Preclinically RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma PKC-delta/epsilon mediate ERK activation in uveal melanoma with GNAQ pathway mutatio
Slide 10: Rare Oncology Indication Comps: IDE196 Potential Addressable Market
Rare Oncology Indication Comps IDE196 Opportunity – Potential Addressable Market Solid Tumors Having GNAQ/11 Hotspot Mutations GNAQ/GNA11 Hotspot Patients in US & EU5 (Patients in 1,000’s) US and EU5 ~3.5 K GNAQ/11 Metastatic Uveal Melanoma (MUM) ~2.5 K GNAQ/11 Other Solid Tumors (Hotspot) ROS1 Adva
Slide 11: IDE196 Development Plan
MUM Monotherapy IDE196 Development Plan Multiple Opportunities to Generate Program Value GNAQ/GNA11 Basket Trial Combinations GNAQ/GNA11 Mediated Diseases Targeting FPI in Q1 2020 for Single-Arm Ph2 Registration Enabling Trial in MUM Potential for US Accelerated Approval FPI achieved for basket tria
Slide 12: IDEAYA Synthetic Lethality Approach
IDEAYA Synthetic Lethality Approach Synthetic Lethality Background Synthetic Lethality (SL) Platform & Capabilities Emerging Class of Precision Medicine Targets TSG = tumor suppressor gene Generating, validating and integrating vast synthetic lethality data sets: Discovery of novel precision medicin
Slide 13: IDEAYA Synthetic Lethality Pipeline
Today IDEAYA Synthetic Lethality Pipeline IDEAYA is advancing the next generation of biomarker-enabled Synthetic Lethality programs HRD = Homologous Recombination Deficiency, MSI = Microsatellite Instability MAT2A MTAP Deletion PARG Replication Stress Polq HRD Dual CRISPR SL Targets PARP HRD/BRCA Ly
Slide 14: MAT2A Inhibition is Synthetic Lethal with MTAP Deletion
MAT2A Inhibition is Synthetic Lethal with MTAP Deletion MTAP Deletion Prevalence ~15% of all Solid Tumors MTAP Deletion Prevalence MTAP-MAT2A SL Biology Data from The Cancer Genome Atlas in cBioPortal Cancer Type N MTAP Deletions (%) Glioblastoma 592 41 Mesothelioma 87 32 Esophageal 95 28 Bladder 41
Slide 15: MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-/- Cell Line
IDEAYA MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-/- Cell Line & PD Modulation of SAM Levels PD Modulation: SAM Levels in HCT116 Cell Line Synthetic Lethality in HCT116 Cell Line IDB361 IDEAYA Data Structurally Enabled Lead Optimization IDB proprietary MAT2Ai co-crystal structure (1.33
Slide 16: MAT2A Inhibitors Demonstrate Tumor Regression in HCT116 MTAP-/- Xenograft
IDEAYA MAT2A inhibitors demonstrate tumor regression in vivo in HCT116 MTAP-/- xenograft model Lead series of IDEAYA MAT2A inhibitors Demonstrate ~60-100% tumor growth inhibition (TGI) at efficacious dose ranges of 3 to 30 mg/kg QD Comparable to higher TGI than Agios AGI-25696 at ≥10-fold lower dose
Slide 17: MAT2A Inhibitors Efficacious in Endogenous MTAP-/- Models
IDEAYA MAT2A inhibitors efficacious in endogenous MTAP-/- models and have potential to differentiate from AG-270 Differentiated safety profile Endogenous model efficacy Efficacious in endogenous in vivo MTAP-/- KP4 and NCI-H2126 xenograft models Superior efficacy compared to Agios published compound
Slide 18: Polq Drug Discovery
Polq Drug Discovery Polq Synthetic Lethality Program Candidate Biomarkers: BRCA/HRD Polq Biomarker Polq synthetic lethality with BRCA1/2 in HCT116 cells Synthetic Lethal Screen with BRCA2 reveals Polq as a top hit Molecular Cell, March 2019, Elledge et al ATPase Polymerase Zahn KE. Nat Struct Mol Bi
Slide 19: Polqi In Vivo Activity
Polqi In Vivo Activity IDEAYA Polq Inhibitor Demonstrates Robust Tumor Reduction as Monotherapy & Combo with PARP in BRCA2-/- In Vivo Model Polqi Cell Viability ATPase inhibitors show dose dependent viability effects in DLD1 BRCA2-/- cell line ATPase inhibitors exhibit modest viability effect on HCC
Slide 20: Werner Drug Discovery and Biomarker
Discovery: multiple hit discovery campaigns using a range of screening formats and compound libraries completed Screening: robust suite of biochemical and biophysical assays to identify WRN inhibitors and differentiate false positives Lead Series: identified a lead series with <10 nM IC50 potency in
Slide 21: WRNi Cellular PD and Viability
Biomarker: dose dependent increase of DNA damage marker gH2AX demonstrated at 48 hours Cell viability: MSI-high specific cell viability effect observed across multiple cell lines; no effect in MSS cell lines WRNi cellular PD and viability WRNi phenocopy genetic knockdown IDEAYA WRN inhibitors demons
Slide 22: PARG Drug Discovery and Biomarker
PARG Drug Discovery and Biomarker PARG Synthetic Lethality Program Candidate Biomarkers: BRCA/BER/Replication Stress PARG’s Key Role in DNA Damage Repair IDEAYA has discovered potent PARG inhibitors SAR guided by structure-based drug design Poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role
Slide 23: IDEAYA's Precision Medicine Oncology Pipeline: Target Milestones through 2020
IDEAYA’s Precision Medicine Oncology Pipeline Target Milestones through 2020 Indication Biomarker Preclinical IND Phase 1 Phase 2 Registration Enabling Target Milestone through 2020 IDE196 PKC inhibitor MUM Mono GNAQ/11 Ph 1/2 Interim Data Q2/Q3 2020 Non-MUM Solid Tumors GNAQ/11 Ph 1/2 Interim Data
IDEAYA Biosciences — JP Morgan Conference January 2020 on 6ix